Paper Review Records
All Paper Review Records
25 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
9
days
Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children
Authors
Sigrid van der Veen; Bart J. Biemond; Marjon H. Cnossen; Pablo Bartolucci; Maria P. Boaro; Betzabel Cajiao Garcia; Raffaella Colombatti; M. D'Agnolo; Karin Fijnvandraat; Anna Collado Gimbert; Amira Idrizovic; Petros Kountouris; Mar Mañú‐Pereira; Elisabetta Mezzalira; Mariane de Montalembert; Erfan Nur; A. Pham Hung D' Alexandry D'Orengiani; Tiziana Sanavia; Saskia E. M. Schols; Marissa J. M. Traets; Minke A. E. Rab; Sara I. Reidel; Anita W. Rijneveld; Yosr Zaouali; Nanda M. Verhoeven‐Duif; Judith J. M. Jans; Eduard J. van BeersShow moreShow less
Affiliations
1. Center for Benign Hematology, Thrombosis and Hemostasis – Van Creveldkliniek, University Medical Center Utrecht, Utrecht University Utrecht the Netherlands; 2. Section Metabolic Diagnostics, Department of Genetics University Medical Centre Utrecht, Utrecht University Utrecht the Netherlands; 3. Department of Hematology Amsterdam University Medical Center Amsterdam the Netherlands; 4. Department of Pediatric Hematology and Oncology, Erasmus MC ‐ Sophia Children's Hospital Erasmus University Medical Center Rotterdam Rotterdam the Netherlands; 5. University Paris‐Est‐Créteil, IMRB, Inserm U955, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center‐UMGGR Creteil France; 6. UOC Oncoematologia Pediatrica, Azienda Ospedale‐Università Padova Padua Italy; 7. Department of Women's and Children's Health University of Padua Padua Italy; 8. Department of Pediatric Hematology Amsterdam UMC, Emma Children's Hospital Amsterdam the Netherlands; 9. Sanquin Research, Department of Molecular Cellular Hemostasis Amsterdam the Netherlands; 10. Rare Anemia Research Laboratory, Vall D'hebron Institut de Recerca Barcelona Spain; 11. Pediatric Oncology and Hematology Department Hospital Universitari Vall D'hebron Barcelona Spain; 12. Genetics and Microbiology Department Universitat Autonoma de Barcelona Barcelona Spain; 13. Molecular Genetics Thalassaemia Department The Cyprus Institute of Neurology and Genetics Nicosia Cyprus; 14. Department of General Pediatrics and Pediatric Infectious Diseases Sickle Cell Center, Necker‐Enfants Malades Hospital Neuilly France; 15. Department of Blood Cell Research Sanquin Research and Landsteiner Laboratory Amsterdam the Netherlands; 16. AI and Computational Biomedicine Unit, Department of Medical Sciences University of Torino Turin Italy; 17. Department of Hematology Radboud University Medical Center Nijmegen the Netherlands; 18. Central Diagnostic Laboratory ‐ Research, University Medical Center Utrecht Utrecht the Netherlands; 19. Department of Hematology Erasmus University Medical Center Rotterdam the NetherlandsShow moreShow less
67
days
High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%
Authors
Orianne Wagner‐Ballon; Anne‐Catherine Lhoumeau; Anna Raimbault; Camille Debord; Jean‐Philippe Vial; Valérie Soenen; Mélanie Pannetier; Edouard Bonneville; Elsa Bera; Caroline Bret; Nicolas Chapuis; Véronique Latger‐Cannard; Caroline Mayeur‐Rousse; Véronique Harrivel; François Vergez; Marie Loosveld; Juliette Vo Xuan; Stéphanie Mathis; Gérard Socié; Flore Sicre de Fontbrune; Régis Peffault de Latour; Bernard Drenou; Agathe Debliquis; Magali Le Garff‐Tavernier; the French PNH working group CytHem‐HPNShow moreShow less
Affiliations
1. Département Hématologie et Immunologie Biologiques APHP Hôpitaux Universitaires Henri Mondor Créteil France; 2. Université Paris‐Est Créteil (UPEC), Inserm U955 IMRB Créteil France; 3. Institut Paoli Calmettes, Laboratoire de Biopathologie Marseille France; 4. APHP Hôpital Saint Louis, Service Hématologie Biologique Paris France; 5. CHU Nantes, Laboratoire Hématologie Nantes France; 6. CHU Bordeaux, Laboratoire Hématologie Bordeaux France; 7. CHU Lille, Laboratoire Hématologie Lille France; 8. CHU de Rennes, Laboratoire Hématologie Rennes France; 9. CHU Grenoble, Laboratoire Hématologie Grenoble France; 10. CHU Rouen, Laboratoire Hématologie Rouen France; 11. CHU Montpellier, Laboratoire Hématologie Montpellier France; 12. APHP CHU Cochin, Laboratoire Hématologie Paris France; 13. CHU Nancy, Laboratoire Hématologie Nancy France; 14. CHU Strasbourg, Laboratoire Hématologie Strasbourg France; 15. CHU Amiens, Laboratoire Hématologie Amiens France; 16. CHU Toulouse, Laboratoire Hématologie Toulouse France; 17. CHU Timone, Laboratoire Hématologie Marseille France; 18. APHP Hôpital Saint Louis, Service Hématologie Clinique Paris France; 19. Groupe Hospitalier de la Région Mulhouse Sud Alsace Service Hématologie Clinique Mulhouse France; 20. Groupe Hospitalier de la Région Mulhouse Sud Alsace Laboratoire Hématologie Mulhouse France; 21. APHP Groupe Hospitalier Pitié‐Salpêtrière‐Charles Foix, Sorbonne Université Service D'hématologie Biologique Paris France; 22. Centre de Recherche Des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138 Drug Resistance in Hematological Malignancies Team Paris FranceShow moreShow less
61
days
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN / HMA
Authors
Fieke W. Hoff; Joshua F. Zeidner; Geeta Torlapati; Deedra Nicolet; Krzysztof Mrózek; Ying Huang; Alexander Li; Rina Li Welkie; Ronan T. Swords; Elie Traer; Eytan M. Stein; Tara L. Lin; Maria R. Baer; Vu H. Duong; William G. Blum; Martha L. Arellano; Wendy Stock; Olatoyosi Odenike; Rebecca L. Olin; Catherine C. Smith; Gary J. Schiller; Emily K. Curran; Onyee Chan; Christine McMahon; Michael Hochman; Kieran Sahasrabudhe; Charles Foucar; Jesus Gonzalez‐Lugo; Brittany Knick Ragon; Shivani V. Handa; Nyla A. Heerema; Timothy Chen; Molly Martycz; Mona Stefanos; Sonja G. Marcus; Leonard Rosenberg; Brian J. Druker; Ross L. Levine; Amy Burd; Ashley O. Yocum; Uma M. Borate; Alice S. Mims; Ann‐Katrin Eisfeld; John C. Byrd; Yazan F. MadanatShow moreShow less
Affiliations
1. National Heart, Lung, and Blood Institute National Institutes of Health Bethesda Maryland USA; 2. Division of Hematology, Department of Medicine, Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina USA; 3. The James Cancer Hospital The Ohio State University Columbus Ohio USA; 4. Clara D. Bloomfield Center for Leukemia Outcomes Research The Ohio State University Comprehensive Cancer Center Columbus Ohio USA; 5. Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA; 6. Division of Hematology and Medical Oncology, Knight Cancer Institute Oregon Health & Science University Portland Oregon USA; 7. Leukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York New York USA; 8. Division of Hematologic Malignancies University of Kansas Medical Center Kansas City Kansas USA; 9. Department of Medicine University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland USA; 10. Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta Georgia USA; 11. Section of Hematology/Oncology University of Chicago Chicago Illinois USA; 12. Division of Hematology and Oncology University of California, San Francisco San Francisco California USA; 13. Department of Medicine, Hematology/Oncology David Geffen School of Medicine at University of California, Los Angeles Los Angeles California USA; 14. Division of Hematology & Oncology University of Cincinnati Cincinnati Ohio USA; 15. Malignant Hematology Department H. Lee Moffitt Cancer Center Tampa Florida USA; 16. Division of Hematology, Department of Medicine University of Colorado School of Medicine Aurora Colorado USA; 17. Division of Hematology University of Wisconsin, Carbone Cancer Center Madison Wisconsin USA; 18. Department of Internal Medicine, Division of Hematology and Oncology University of New Mexico Albuquerque New Mexico USA; 19. Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine Charlotte North Carolina USA; 20. Blood Cancer United Washington DC USA; 21. UPMC Hillman Cancer Center University of Pittsburgh Pittsburgh Pennsylvania USAShow moreShow less
83
days
Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial
Authors
Santosh Kumar Singh; Rahil Arora; Suman Kumar Pramanik; Abhishek Kumar; Alok Singh; Shantanu Khanna; Nitya Malhotra; Pranay Juneja; Netri Upadhyay; Uday YanamandraShow moreShow less
Affiliations
1. Department of Internal Medicine Armed Forces Medical College (AFMC) Pune India; 2. Department of Medical Research Armed Forces Medical College (AFMC) Pune India; 3. Department of Medicine Military Hospital Kirkee Pune India; 4. Department of Radiology Command Hospital, Air Force Bangalore India; 5. Department of Medicine, Government Medical College and Hospital Chandigarh India; 6. Department of Medicine, JNMC, DMIHER Wardha IndiaShow moreShow less
30
days
Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments ( PQRST )” Trial
Authors
Betty K. Hamilton; Lynn Onstad; Paul A. Carpenter; Joseph Pidala; George Chen; Corey Cutler; Najla El Jurdi; Nosha Farhadfar; Mark Juckett; Carrie L. Kitko; Catherine J. Lee; Stephanie J. LeeShow moreShow less
Affiliations
1. Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA; 2. Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA; 3. H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA; 4. University of Texas MD Anderson Cancer Center Houston Texas USA; 5. Dana Farber Cancer Institute Boston Massachusetts USA; 6. National Cancer Institute, National Institutes of Health Bethesda Maryland USA; 7. Sarah Cannon Transplant and Cellular Program, Methodist Hospital San Antonio Texas USA; 8. University of Minnesota Minneapolis Minnesota USA; 9. Vanderbilt University Medical Center Nashville Tennessee USAShow moreShow less
236
days
Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B‐ ALL
Authors
Binjun Xiong; Jianwen Zhou; Xuhan Zhang; Yance Feng; Jie Cheng; Hui Shi; Qian Li; Wenli Tang; Yali Shen; Fen Zhou; Shaoyan Hu; Hua YouShow moreShow less
Affiliations
1. Precision Oncology and Intelligent Theranostics Laboratory Children's Hospital of Chongqing Medical University Chongqing China; 2. Ministry of Education Key Laboratory of Child Development and Disorders National Clinical Research Center for Children and Adolescents' Health and Diseases Chongqing China; 3. Department of Hematology and Oncology Children's Hospital Affiliated to Zhengzhou University (Zhengzhou Children's Hospital) Zhengzhou China; 4. Division of Life Sciences and Medicine, Department of Pediatric Hematology and Oncology The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), University of Science and Technology of China Hefei China; 5. Department of Hematology and Oncology Anhui Provincial Children's Hospital Hefei China; 6. Department of Pediatric Hematology and Oncology Children's Hospital of Chongqing Medical University Chongqing China; 7. Department of Pediatrics Union Hospital, Tongji Medical College of Huazhong University of Science and Technology Wuhan China; 8. Department of Hematology and Oncology Children's Hospital of Soochow University Suzhou China; 9. Department of Pediatric Oncology Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China Chengdu ChinaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days